Literature DB >> 22406404

Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.

Shannon Puhalla1, Saveri Bhattacharya, Nancy E Davidson.   

Abstract

The treatment of breast cancer is driven by subtype classification, of which the assessment of hormone receptor status is one of the important determinants of therapy. The use of hormonal therapy to treat estrogen-receptor positive breast cancer has been studied for over a century and is one of the well-described uses of personalized medicine. In this review, we will describe the classification of hormone receptor status and the various endocrine treatment strategies. Opportunities for personalization of care are illustrated.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22406404      PMCID： PMC5528370          DOI： 10.1016/j.molonc.2012.02.003

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


  103 in total

1.  Metabolic gene polymorphism frequencies in control populations.

Authors:  S Garte; L Gaspari; A K Alexandrie; C Ambrosone; H Autrup; J L Autrup; H Baranova; L Bathum; S Benhamou; P Boffetta; C Bouchardy; K Breskvar; J Brockmoller; I Cascorbi; M L Clapper; C Coutelle; A Daly; M Dell'Omo; V Dolzan; C M Dresler; A Fryer; A Haugen; D W Hein; A Hildesheim; A Hirvonen; L L Hsieh; M Ingelman-Sundberg; I Kalina; D Kang; M Kihara; C Kiyohara; P Kremers; P Lazarus; L Le Marchand; M C Lechner; E M van Lieshout; S London; J J Manni; C M Maugard; S Morita; V Nazar-Stewart; K Noda; Y Oda; F F Parl; R Pastorelli; I Persson; W H Peters; A Rannug; T Rebbeck; A Risch; L Roelandt; M Romkes; D Ryberg; J Salagovic; B Schoket; J Seidegard; P G Shields; E Sim; D Sinnet; R C Strange; I Stücker; H Sugimura; J To-Figueras; P Vineis; M C Yu; E Taioli
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-12       Impact factor: 4.254

2.  Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.

Authors:  J Abrams; J Aisner; C Cirrincione; D A Berry; H B Muss; M R Cooper; I C Henderson; L Panasci; J Kirshner; J Ellerton; L Norton
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

3.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

4.  Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years.

Authors:  H J Stewart; R J Prescott; A P Forrest
Journal:  J Natl Cancer Inst       Date:  2001-03-21       Impact factor: 13.506

5.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

6.  Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.

Authors:  F Boccardo; A Rubagotti; D Amoroso; M Mesiti; D Romeo; P Sismondi; M Giai; F Genta; P Pacini; V Distante; A Bolognesi; D Aldrighetti; A Farris
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

7.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

8.  Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

Authors:  B Fisher; J Dignam; J Bryant; N Wolmark
Journal:  J Natl Cancer Inst       Date:  2001-05-02       Impact factor: 13.506

9.  Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.

Authors:  T Delozier; M Spielmann; J Macé-Lesec'h; M Janvier; C Hill; B Asselain; J P Julien; B Weber; L Mauriac; J C Petit; P Kerbrat; J P Malhaire; P Vennin; B Leduc; M Namer
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

Review 10.  LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action.

Authors:  P Limonta; M Montagnani Marelli; R M Moretti
Journal:  Expert Opin Investig Drugs       Date:  2001-04       Impact factor: 6.206
View more
  17 in total

1.  The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.

Authors:  James D Joseph; Beatrice Darimont; Wei Zhou; Alfonso Arrazate; Amy Young; Ellen Ingalla; Kimberly Walter; Robert A Blake; Jim Nonomiya; Zhengyu Guan; Lorna Kategaya; Steven P Govek; Andiliy G Lai; Mehmet Kahraman; Dan Brigham; John Sensintaffar; Nhin Lu; Gang Shao; Jing Qian; Kate Grillot; Michael Moon; Rene Prudente; Eric Bischoff; Kyoung-Jin Lee; Celine Bonnefous; Karensa L Douglas; Jackaline D Julien; Johnny Y Nagasawa; Anna Aparicio; Josh Kaufman; Benjamin Haley; Jennifer M Giltnane; Ingrid E Wertz; Mark R Lackner; Michelle A Nannini; Deepak Sampath; Luis Schwarz; Henry Charles Manning; Mohammed Noor Tantawy; Carlos L Arteaga; Richard A Heyman; Peter J Rix; Lori Friedman; Nicholas D Smith; Ciara Metcalfe; Jeffrey H Hager
Journal:  Elife       Date:  2016-07-13       Impact factor: 8.140

2.  Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.

Authors:  Heather M Brechbuhl; Jessica Finlay-Schultz; Tomomi M Yamamoto; Austin E Gillen; Diana M Cittelly; Aik-Choon Tan; Sharon B Sams; Manoj M Pillai; Anthony D Elias; William A Robinson; Carol A Sartorius; Peter Kabos
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

Review 3.  Role of dietary bioactive natural products in estrogen receptor-positive breast cancer.

Authors:  Min Ji Bak; Soumyasri Das Gupta; Joseph Wahler; Nanjoo Suh
Journal:  Semin Cancer Biol       Date:  2016-03-22       Impact factor: 15.707

Review 4.  Development of Companion Diagnostics.

Authors:  David A Mankoff; Christine E Edmonds; Michael D Farwell; Daniel A Pryma
Journal:  Semin Nucl Med       Date:  2016-01       Impact factor: 4.446

5.  Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy.

Authors:  Deanna M Janzen; Miguel A Rosales; Daniel Y Paik; Daniel S Lee; Daniel A Smith; Owen N Witte; M Luisa Iruela-Arispe; Sanaz Memarzadeh
Journal:  Cancer Res       Date:  2013-06-06       Impact factor: 12.701

6.  LyeTxI-b, a Synthetic Peptide Derived From a Spider Venom, Is Highly Active in Triple-Negative Breast Cancer Cells and Acts Synergistically With Cisplatin.

Authors:  Joaquim Teixeira de Avelar Júnior; Edleusa Lima-Batista; Célio José Castro Junior; Adriano Monteiro de Castro Pimenta; Raquel Gouvêa Dos Santos; Elaine Maria Souza-Fagundes; Maria Elena De Lima
Journal:  Front Mol Biosci       Date:  2022-05-04

Review 7.  Current medical treatment of estrogen receptor-positive breast cancer.

Authors:  Franco Lumachi; Davide A Santeufemia; Stefano Mm Basso
Journal:  World J Biol Chem       Date:  2015-08-26

Review 8.  Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.

Authors:  Mridul Datta; Gary G Schwartz
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-07       Impact factor: 6.312

9.  Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer.

Authors:  Christopher G Mayne; Weiyi Toy; Kathryn E Carlson; Trusha Bhatt; Sean W Fanning; Geoffrey L Greene; Benita S Katzenellenbogen; Sarat Chandarlapaty; John A Katzenellenbogen; Emad Tajkhorshid
Journal:  Mol Cancer Res       Date:  2021-05-21       Impact factor: 5.852

10.  Effects of Melandrium firmum Rohrbach on RANKL‑induced osteoclast differentiation and OVX rats.

Authors:  Minsun Kim; Jae-Hyun Kim; Sooyeon Hong; Boguen Kwon; Eun-Young Kim; Hyuk-Sang Jung; Youngjoo Sohn
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.